Cargando…
Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
BACKGROUND: Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited therapeutic options. BRCA2 mutations are identified in up to 14% of ACs and, differently from other...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064505/ https://www.ncbi.nlm.nih.gov/pubmed/36998040 http://dx.doi.org/10.1186/s12957-023-02976-0 |
_version_ | 1785017906438864896 |
---|---|
author | Mauri, Gianluca Gori, Viviana Patelli, Giorgio Roazzi, Laura Rizzetto, Francesco De Carlis, Luciano Mariani, Anna Cavallari, Ugo Prada, Elisabetta Cipani, Tiziana Aquilano, Maria Costanza Bonoldi, Emanuela Vanzulli, Angelo Siena, Salvatore Sartore-Bianchi, Andrea |
author_facet | Mauri, Gianluca Gori, Viviana Patelli, Giorgio Roazzi, Laura Rizzetto, Francesco De Carlis, Luciano Mariani, Anna Cavallari, Ugo Prada, Elisabetta Cipani, Tiziana Aquilano, Maria Costanza Bonoldi, Emanuela Vanzulli, Angelo Siena, Salvatore Sartore-Bianchi, Andrea |
author_sort | Mauri, Gianluca |
collection | PubMed |
description | BACKGROUND: Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited therapeutic options. BRCA2 mutations are identified in up to 14% of ACs and, differently from other tumor types, therapeutic implications remain to be defined. Here, we report a clinical case of a metastatic AC patient in which the identification of a BRCA2 germline mutation drove a personalized multimodal approach with curative-intent. CASE PRESENTATION: A 42-year-old woman diagnosed with stage IV BRCA2 germline mutant AC underwent platinum-based first line treatment achieving major tumor response but also life-threatening toxicity. Based on this, as well as on molecular findings and expected low impact of available systemic treatment options, the patient underwent radical complete surgical resection of both primary tumor and metastatic lesions. Following an isolated retroperitoneal nodal recurrence, given the expected enhanced sensitivity to radiotherapy in BRCA2 mutant cancers, the patient underwent imaging-guided radiotherapy leading to long-lasting complete tumor remission. After more than 2 years, the disease remains radiologically and biochemically undetectable. The patient accessed a dedicated screening program for BRCA2 germline mutation carriers and underwent prophylactic bilateral oophorectomy. CONCLUSIONS: Even considering the intrinsic limitations of a single clinical report, we suggest that the finding of BRCA germline mutations in ACs should be taken into consideration, together with other clinical variables, given their potential association with remarkable response to cytotoxic chemotherapy that might be burdened with enhanced toxicity. Accordingly, BRCA1/2 mutations might offer the opportunity of personalizing treatment beyond PARP inhibitors up to the choice of a multimodal approach with curative-intent. |
format | Online Article Text |
id | pubmed-10064505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100645052023-04-01 Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report Mauri, Gianluca Gori, Viviana Patelli, Giorgio Roazzi, Laura Rizzetto, Francesco De Carlis, Luciano Mariani, Anna Cavallari, Ugo Prada, Elisabetta Cipani, Tiziana Aquilano, Maria Costanza Bonoldi, Emanuela Vanzulli, Angelo Siena, Salvatore Sartore-Bianchi, Andrea World J Surg Oncol Case Report BACKGROUND: Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited therapeutic options. BRCA2 mutations are identified in up to 14% of ACs and, differently from other tumor types, therapeutic implications remain to be defined. Here, we report a clinical case of a metastatic AC patient in which the identification of a BRCA2 germline mutation drove a personalized multimodal approach with curative-intent. CASE PRESENTATION: A 42-year-old woman diagnosed with stage IV BRCA2 germline mutant AC underwent platinum-based first line treatment achieving major tumor response but also life-threatening toxicity. Based on this, as well as on molecular findings and expected low impact of available systemic treatment options, the patient underwent radical complete surgical resection of both primary tumor and metastatic lesions. Following an isolated retroperitoneal nodal recurrence, given the expected enhanced sensitivity to radiotherapy in BRCA2 mutant cancers, the patient underwent imaging-guided radiotherapy leading to long-lasting complete tumor remission. After more than 2 years, the disease remains radiologically and biochemically undetectable. The patient accessed a dedicated screening program for BRCA2 germline mutation carriers and underwent prophylactic bilateral oophorectomy. CONCLUSIONS: Even considering the intrinsic limitations of a single clinical report, we suggest that the finding of BRCA germline mutations in ACs should be taken into consideration, together with other clinical variables, given their potential association with remarkable response to cytotoxic chemotherapy that might be burdened with enhanced toxicity. Accordingly, BRCA1/2 mutations might offer the opportunity of personalizing treatment beyond PARP inhibitors up to the choice of a multimodal approach with curative-intent. BioMed Central 2023-03-31 /pmc/articles/PMC10064505/ /pubmed/36998040 http://dx.doi.org/10.1186/s12957-023-02976-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Mauri, Gianluca Gori, Viviana Patelli, Giorgio Roazzi, Laura Rizzetto, Francesco De Carlis, Luciano Mariani, Anna Cavallari, Ugo Prada, Elisabetta Cipani, Tiziana Aquilano, Maria Costanza Bonoldi, Emanuela Vanzulli, Angelo Siena, Salvatore Sartore-Bianchi, Andrea Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report |
title | Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report |
title_full | Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report |
title_fullStr | Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report |
title_full_unstemmed | Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report |
title_short | Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report |
title_sort | multimodal treatment with curative intent in a germline brca2 mutant metastatic ampullary adenocarcinoma: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064505/ https://www.ncbi.nlm.nih.gov/pubmed/36998040 http://dx.doi.org/10.1186/s12957-023-02976-0 |
work_keys_str_mv | AT maurigianluca multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT goriviviana multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT patelligiorgio multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT roazzilaura multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT rizzettofrancesco multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT decarlisluciano multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT marianianna multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT cavallariugo multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT pradaelisabetta multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT cipanitiziana multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT aquilanomariacostanza multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT bonoldiemanuela multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT vanzulliangelo multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT sienasalvatore multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport AT sartorebianchiandrea multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport |